Calidi Biotherapeutics In...

AMEX: CLDI · Real-Time Price · USD
5.28
0.24 (4.76%)
At close: Aug 15, 2025, 3:59 PM
5.24
-0.76%
After-hours: Aug 15, 2025, 07:55 PM EDT

Calidi Biotherapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Revenue
1.5M 1.5M 1.5M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
1.19M 1.16M 1.14M 1.51M 1.22M 838K 464K 100K n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
-439K -410K -390K -1.51M -1.22M -838K -464K -100K n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-19.98M -20.09M -21.78M -27.57M -29.57M -25.29M -20.57M -13.46M -7.3M -6.17M -4.67M -2.56M -2.59M -2.24M -1.71M -1.1M -10K
Interest Income
n/a n/a n/a n/a n/a 493.56K 493.56K 493.56K 493.56K 160K 176.5K 176.5K 176.5K 16.5K n/a n/a n/a
Pretax Income
-20.03M -20.03M -22.2M -26.28M -23.23M -21.66M -16.59M -10.81M -8.1M 255.92K 3.88M 10.61M 9.09M 4.92M 3.46M -833.29K -10K
Net Income
-19.85M -19.9M -22.14M -26.27M -23.25M -29.98M -29.22M -28.74M -32.07M -15.41M -7.49M -3.22M 1.31M -2.86M -4.32M -833.29K -10K
Selling & General & Admin
10.99M 11.53M 12.52M 15.81M 16.61M 14.5M 12.89M 10.11M 7.3M 6.17M 4.67M 2.56M 2.59M 2.24M 1.71M 1.1M 10K
Research & Development
8.99M 8.56M 8.88M 11.02M 12.12M 13.13M 13.01M 11.31M 10.01M 6.83M 4.21M 1.95M n/a n/a n/a n/a n/a
Other Expenses
n/a n/a n/a n/a n/a -16K -21K -34K -34K -18K -13K n/a n/a n/a n/a n/a n/a
Operating Expenses
19.98M 20.09M 21.4M 26.83M 28.73M 24.45M 20.1M 13.36M 7.3M 6.17M 4.67M 2.56M 2.59M 2.24M 1.71M 1.1M 10K
Interest Expense
531K 752K 933K 980K 1.07M 1.1M 1.07M 945K 650K 344K 127K 91K 62K 62K 62K n/a n/a
Selling & Marketing Expenses
n/a n/a -374K -738K -838K -2.7M -3.09M -2.44M -4.41M -2.55M -1.79M -2.08M n/a n/a n/a n/a n/a
Cost & Expenses
19.98M 20.09M 21.78M 27.57M 29.57M 25.29M 20.57M 13.46M 7.3M 6.17M 4.67M 2.56M 2.59M 2.24M 1.71M 1.1M 10K
Income Tax Expense
11K 15K 16K 10K 20K 89.95K 151.42K 297.72K 490.41K 412.46K 346.99K 203.69K n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
2.88M 2.25M 664.41K 649.39K 442.22K 295.08K 294.83K 118.77K 81.99K 81.99K 81.99K 219.9K 238.63K 238.63K 238.63K 238.63K 238.63K
Shares Outstanding (Diluted)
2.88M 2.25M 664.41K 649.39K 442.22K 295.08K 294.83K 118.77K 81.99K 81.99K 81.99K 219.9K 238.63K 238.63K 238.63K 238.63K 238.63K
EPS (Basic)
-14.37 -29.18 -51.39 -76.82 -85.99 -121.03 -123.61 -127.25 -108 -38.76 -5.64 43.68 37.92 20.48 14.36 -3.52 -0.04
EPS (Diluted)
-14.37 -29.18 -51.39 -76.82 -85.99 -121.03 -123.61 -127.25 -108 -38.76 -5.64 43.68 37.92 20.48 14.36 -3.52 -0.04
EBITDA
-18.28M -17.73M -19.73M -23.8M -20.69M -17.08M -15.81M -16.95M -20.93M -19.8M -15.01M -9M -4.77M -4.42M -3.89M -1.1M -10K
EBIT
-19.5M -19.28M -21.26M -25.3M -22.15M -20.84M -20.11M -19.76M -23.4M -15.07M -7.36M -3.13M 1.38M -2.8M -4.26M -833.29K -10K
Depreciation & Amortization
1.58M 1.55M 1.53M 1.51M 1.46M 1.45M 1.26M 983K 700K 336K 153K 62K n/a n/a n/a n/a n/a